Bringing medtech innovation to market requires more than a breakthrough technology. It takes the right capital, evidence, reimbursement strategy, and path to scale. In this episode of PwC’s Next in Health, Glenn Hunzinger and Brent Hill continue their conversation with Darshana Zaveri, co-founder and managing partner of Catalyst Health Ventures, and Geoff Pardo, general partner at Gilde Healthcare, exploring what it takes to turn promising medtech innovation into sustainable growth and patient impact. From funding and clinical evidence to M&A, product-market fit, and capital efficiency, the conversation examines how founders, investors, and strategic players are navigating an increasingly complex market.

Discussion highlights:

• The evolving funding environment for early-stage medtech companies and what investors are looking for today
• Why clinical, regulatory, and reimbursement strategies increasingly need to be considered together
• The forces driving medtech M&A, including portfolio optimization, new buyers, and the need for growth
• How companies and investors can build toward meaningful value inflection points and potential exits
• The importance of capital discipline, investor alignment, strong leadership teams, and product-market fit
• Where investors see the greatest opportunities for MedTech innovation over the next three to five years and beyond

Speakers:

Glenn Hunzinger, US Health Industries Leader, PwC
Darshana Zaveri, Co-founder and Managing Partner, Catalyst Health Ventures
Geoff Pardo, General Partner, Gilde Healthcare
Brent Hill, Managing Director, Medtech Strategy, PwC

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.